Evidence map›Paper›PMID 34962661›Full record

Observational studyClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2022

Cat allergen exposure in a naturalistic exposure chamber: A prospective observational study in cat-allergic subjects.

William H Yang, Suzanne Kelly, Laura Haya, Rym Mehri, Divya Ramesh, Michelle DeVeaux, Claire Q Wang, Pretty Meier, Sumit Narula, Furat Shawki and 3 more

Open access · hybridAbstract readObservational Study
In one paragraph

Observational study in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Clinical validation of controlled exposure to cat dander in the Specialized Particulate Control Environmental Exposure Unit (SPaC-EEU).Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2025
    Article
  3. Review
  4. Article
  5. [Research progress and clinical application of allergen nasal provocation test].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2023
    Review
  6. Cat allergen exposure in a naturalistic exposure chamber: A prospective observational study in cat-allergic subjects.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2022
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

William H YangRed Maple Trials, Inc., Ottawa, Ontario, Canada.
Suzanne KellyRed Maple Trials, Inc., Ottawa, Ontario, Canada.
Laura HayaRed Maple Trials, Inc., Ottawa, Ontario, Canada.
Rym MehriRed Maple Trials, Inc., Ottawa, Ontario, Canada.
Divya RameshRegeneron Pharmaceuticals, Tarrytown, New York, USA.
Michelle DeVeauxRegeneron Pharmaceuticals, Tarrytown, New York, USA.
Claire Q WangRegeneron Pharmaceuticals, Tarrytown, New York, USA.
Pretty MeierRegeneron Pharmaceuticals, Tarrytown, New York, USA.
Sumit NarulaRegeneron Pharmaceuticals, Tarrytown, New York, USA.
Furat ShawkiRegeneron Pharmaceuticals, Tarrytown, New York, USA.
Ryan PenningtonRegeneron Pharmaceuticals, Tarrytown, New York, USA.
Lorah PerleeRegeneron Pharmaceuticals, Tarrytown, New York, USA.ORCID 0000-0001-6581-5540
Meagan P O'BrienRegeneron Pharmaceuticals, Tarrytown, New York, USA.
Regeneron (United States) · USRobarts Clinical Trials · CA

Funding

Regeneron Pharmaceuticals
6 · The paper itself

Abstract

backgroundTo determine the proportion and reproducibility of cat-allergic mild asthmatics with early asthmatic response (EAR) during cat allergen exposure in a naturalistic exposure chamber (NEC).

methodsThis was a prospective, observational study in 30 cat-allergic mild asthmatics who received two 180-min cat-allergen (Felis domesticus allergen 1 [Fel d 1]) challenges 27 days apart in an NEC.

resultsAn EAR (≥20% reduction from baseline in forced expiratory volume in 1 s [FEV1]) was observed in 67% and 52% of subjects at first and second NEC exposure, respectively, with similar median time to EAR; 44% of subjects had an EAR on days 1 and 28. Late asthmatic response (≥15% reduction in FEV1 within 24 h of NEC exit) was observed in 33% of subjects following either exposure. Average FEV1 and total nasal symptom score during NEC exposure were highly correlated within subjects between NEC exposures (r = 0.91, p < 0.0001; r = 0.73, p < 0.001), but total ocular symptom score was not. Time to EAR, but not average FEV1, was significantly associated with NEC Fel d 1 concentration, which was variable. There were no serious adverse events; 12/30 subjects experienced 20 adverse events (including asthma, 10%; headache, 10%).

conclusionsThe NEC model demonstrates that average FEV1 change is highly reproducible and has a low correlation with cat allergen levels. However, time to EAR and incidence of EAR are less reproducible and are highly correlated with NEC allergen levels. Average FEV1, rather than incidence of EAR or time to EAR, could be considered as an endpoint for interventional trials testing cat-specific anti-allergy therapies using an NEC.

Indexed as

AsthmaHypersensitivityAllergensBronchial Provocation TestsForced Expiratory VolumeHumansProspective StudiesReproducibility of ResultsAllergensallergy treatmentasthmachallenge tests

Identifiers

PMID34962661
PMCPMC9303194
OpenAlexW4200470755

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.